Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ines Figueiredo

Showing results (21-30 of 72) with videos related to

Pageof 8
Sort By:
European Urology|December 3, 2014
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetateRoberta Ferraldeschi, Daniel Nava Rodrigues, Ruth Riisnaes, et al.
European Urology|March 8, 2021
CD38 in Advanced Prostate CancersChristina Guo, Mateus Crespo, Bora Gurel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2021
Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB DependenciesYi Liang, Sujeeve Jeganathan, Stefano Marastoni, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 31, 2023
Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate CancerAntje Neeb, Ines Figueiredo, Bora Gurel, et al.
The Journal of Clinical Investigation|October 19, 2018
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancerAdam Sharp, Ilsa Coleman, Wei Yuan, et al.
British Journal of Cancer|September 18, 2015
PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patientsElizabeth A Punnoose, Roberta Ferraldeschi, Edith Szafer-Glusman, et al.
European Urology|July 13, 2020
Elucidating Durable Responses to Immune Checkpoint InhibitionPasquale Rescigno, Caterina Aversa, Mateus Crespo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2024
CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive TumorsSophie Archer, Phillip M Brailey, Minjung Song, et al.
The Journal of Clinical Investigation|April 1, 2026
Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancersAlec Paschalis, Ines Figueiredo, Denisa Bogdan, et al.
Investigational New Drugs|May 15, 2026
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancerKhobe Chandran, Christina Guo, Simon Pacey, et al.
Pageof 8

Showing results (21-30 of 72) with videos related to

Sort By:
Pageof 8
European Urology|December 3, 2014
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetateRoberta Ferraldeschi, Daniel Nava Rodrigues, Ruth Riisnaes, et al.
European Urology|March 8, 2021
CD38 in Advanced Prostate CancersChristina Guo, Mateus Crespo, Bora Gurel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2021
Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB DependenciesYi Liang, Sujeeve Jeganathan, Stefano Marastoni, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 31, 2023
Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate CancerAntje Neeb, Ines Figueiredo, Bora Gurel, et al.
The Journal of Clinical Investigation|October 19, 2018
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancerAdam Sharp, Ilsa Coleman, Wei Yuan, et al.
British Journal of Cancer|September 18, 2015
PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patientsElizabeth A Punnoose, Roberta Ferraldeschi, Edith Szafer-Glusman, et al.
European Urology|July 13, 2020
Elucidating Durable Responses to Immune Checkpoint InhibitionPasquale Rescigno, Caterina Aversa, Mateus Crespo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2024
CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive TumorsSophie Archer, Phillip M Brailey, Minjung Song, et al.
The Journal of Clinical Investigation|April 1, 2026
Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancersAlec Paschalis, Ines Figueiredo, Denisa Bogdan, et al.
Investigational New Drugs|May 15, 2026
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancerKhobe Chandran, Christina Guo, Simon Pacey, et al.
Pageof 8